EP262, a first-in-class oral Mas-related G protein-coupled receptor X2 antagonist with the potential to treat a broad range of inflammatory disorders, has demonstrated proof-of-mechanism in chronic.
Vertex Pharma to acquire Alpine Immune Sciences for $4.9 billion to strengthen scientific innovation financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire .
Vertex (VRTX) Enters Into Agreement to Acquire Alpine Immune Sciences (ALPN) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Vertex Pharmaceuticals Incorporated: Vertex Enters Into Agreement to Acquire Alpine Immune Sciences finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.